-

02:09:24 PM

ORYZF Stock News

ORYZF - Oryzon Genomics S.A.

03/25/22 8:00 AM

OTC : ORYZF

ORYZON to Give Updates on Corporate Progress in March and April

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in

RHEA-AI

neutral

03/21/22 8:00 AM

OTC : ORYZF

fda approval

ORYZON Announces FDA Approval of IND for FRIDA, a Phase Ib Trial With Iadademstat in R/R AML FLT3mut+ Patients

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical

RHEA-AI

very positive

02/14/22 8:00 AM

OTC : ORYZF

ORYZON to Give Updates on Corporate Progress in February and March

Oryzon Genomics, S.A. (ISIN Code: ES0167733015,

RHEA-AI

neutral

02/10/22 7:00 AM

OTC : ORYZF

Oryzon Genomics (ORY): Planning Iadademstat's Path to Market

Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific demethylase 1A, or LSD1, inhibitors). The company's R&D strategy has been to select indications where there

RHEA-AI

neutral

02/07/22 8:00 AM

OTC : ORYZF

ORYZON Reports Results and Corporate Update for Q4 and Year Ended December 31, 2021

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the

RHEA-AI

neutral

01/11/22 8:00 AM

OTC : ORYZF

clinical trial

ORYZON Announces New Senior VP of Clinical Development and Global Medical Affairs, Continuing its Expansion of US Corporate Activities

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage

RHEA-AI

neutral

01/04/22 8:00 AM

OTC : ORYZF

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop

RHEA-AI

neutral

01/03/22 8:00 AM

OTC : ORYZF

ORYZON to Hold Multiple Corporate Activities in January

Oryzon Genomics, S.A. (ISIN Code:

RHEA-AI

neutral

12/13/21 8:00 AM

OTC : ORYZF

ORYZON at ASH-2021: Iadademstat 36-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Robust efficacy - ORR 78%, of which 62% are CR/CRi 77% of CR/CRi lasting more than 6 months Longest remission beyond 1,000 days, still ongoing Iadademstat and azacitidine combination shows a good safety profile Enrollment in ALICE completed Dosing of iadademstat established MADRID, Spain and

RHEA-AI

neutral

11/22/21 8:00 AM

OTC : ORYZF

ORYZON Announces New Global Chief Business Officer and Expansion of US Corporate Activities

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging

RHEA-AI

neutral